PharmaTutor (December- 2013)
ISSN: 2347 - 7881
Received On: 30/10/2013; Accepted On: 24/11/2013; Published On: 20/12/2013
Authors: D. Nagendrakumar, Reddy VM, Keshavshetti G G, Shardor A G
Department of Pharmaceutics, SVET’s College of Pharmacy,
Humnabad- 585 330 (Karnataka).
ABSTRACT: Sustained release matrix system are favored because of their simplicity, patient compliance etc, than traditional drug delivery which have many drawbacks like repeated administration, fluctuation in blood concentration level etc. For the purpose of enhancement the bioavailability of furosemide, a dosage form with sustained release of furosemide was designed in this study.
Sustained release tablets of furosemide were fabricated using xanthan gum (13.33 % to 66.67 %). The prepared tablets were evaluated for pre compression and post compression studies like angle of repose, bulk density, tapped density, hardness, weight variation, fraibilty, drug content, in-vitro releaseof drug etc. among the five formulations A better controlled drug release (85 %) was obtained with the matrix tablet SX5containing xanthan gum 66.67%. Short-term stability studies of all formulations indicates that there were no significant changes in drug content and dissolution parameter values after 3 month storage at 40° ± 2°C/75 ± 5% RH.
How to cite this article: Kumar DN, Reddy VM, Keshavshetti GG, Shardor AG, Design and Development of Sustained Release Matrix Tablets of Furosemide, PharmaTutor, 2013, 1(2), 99-105
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1.Wise DL. Handbook of Pharmaceutical Controlled Release Technology. 1st ed. New York: Marcel Dekker Inc; 2005: p.5-24.
2.Gilbert SB, Christopher TR. Modern pharmaceutics. 3rd ed. Revised and expanded. New York: Marcel Dekker Inc 1995. p.575-08.
3.Shargel L, Yu ABC. Modified release drug products. In: Applied Biopharmaceutics and Pharmacokinetics. 4th ed. McGraw Hill 1999; p.169-71.
4.Jantzen GM, Robinson JR, Sustained and controlled-release drug delivery systems, in Banker GS, Rhodes CT (Eds.) Modern Pharmaceutics, Third Edition, Revised and Expanded, Drugs and the Pharmaceutical Sciences, vol 72, Marcell Dekker, Inc. New York 1995: p.575-609
5.ICH Guideline on Stability study; 2005.
6.Cooper J and Gunn C, Powder flow and compaction, In: Carter SJ, editor, Tutorial Pharmacy, New Delhi, CBS Publishers and Distributors 1986; p.211–33.
7.Indian Pharmacopoeia, 4th ed, Vol. II, New Delhi, the Controller of Publications, 1996; p.736.
8.Matthews BR. Regulatory aspects of stability testing in Europe. Drug Dev. Ind. Pharm. 1999; 25: p.831-56.
9.Velasco MV, Munoz A, Jimenez-Castellanos MR, Castellano I, Goni I, Gurruchaga M, et al. In vitro evaluation of sustained-release matrix tablets prepared with new modified polymeric carbohydrates. Int J Pharm 1996;136: p.107-15.
10.Pather SI, Russell I, Syce JA, Neau SH. Sustained release theophylline tablets by direct compression Part 1: formulation and in vitro testing. Int J Pharm 1998;164:1-10.
11.Giunchedi P, Gavini E, Moretti MDL, Pirisino G. Evaluation of alginate compressed matrices as prolonged drug delivery systems. AAPS Pharm Sci Tech 2000;1:E19.
12.Krishnaiah YSR, Karthikeyan RS, Satyanarayana V. A three-layer guar gum matrix tablet for oral controlled delivery of highly soluble metoprolol tartrate. Int J Pharm 2002;241: p.353-66.
13 Sanchez-Lafuente C, Faucci MT, Fernandez-Arevalo M, Alvarez-Fuentes J, Rabasco AM, Mura P, et al. Development of sustained release matrix tablets of didanosine containing methacrylic and ethylcellulosepolymers. Int J Pharm 2002;234: p.213-21.
14.Tiwari SB, Murthy TK, Pai MR, Mehta PR, Chowdary PB. Controlled release formulation of tramadol hydrochloride using hydrophilic and hydrophobic matrix system. AAPS Pharm Sci Tech 2003;4(3): p.1-6.
15.Reddy KR, Mutalik S, Reddy S. Once-daily sustained-release matrix tablets of nicorandil: Formulation and in vitro evaluation. AAPS Pharm Sci Tech 2003;4(4): p.1-9.
16.Pandey VP, Manavalan R, Rajan TS, Ganesh KS. Formulation and release characteristics of sustained release diltiazem hydrochloride tablet. Indian J Pharm Sci 2003; p.65:44-8.
17.Al-Saidan SM, Krishnaiah YR, Satyanarayana V, Bhaskar P, Karthikeyan RS. Pharmacokinetic evaluation of guar gum-based three-layer matrix tablets for oral controlled delivery of highly soluble metoprolol tartrate as a model drug. Eur J Pharm Biopharm 2004;58: p.697-703.
18.Shirwaikar AA, Srinatha A. Sustained release bi-layered tablets of diltiazem hydrochloride using insoluble matrix system. Indian J Pharm Sci 2004;66: p.433-7.
19.Ceballos A, Cirri M, Maestrelli F, Corti G, Mura P. Influence of formulation and process variables on in vitro release of theophylline from directly-compressed eudragit matrix tablets. Farmaco 2005;60: p.913-8.
20.Kuksal A, Tiwary AK, Jain NK, Jain S. Formulation and in vitro, in vivo evaluation of extended-release matrix tablet of zidovudine: Influence of combination of hydrophilic and hydrophobic matrix formers. AAPS Pharm Sci Tech 2006;7(1):E1-E9.
21.Emami J, Tajeddin M and Ahmadi F. Preparation and in vitro evaluation of sustained release matrix tablets of flutamide using synthetic and naturally occurring polymers. Int J Pharm Res. 2008;7(4): p.247-57.
22.Vuorinen S, Heinamaki J, Antikainen O, Lahcini M, Repo T, Yliruusi J, et al. Sugar end-capped poly-D,L-lactides as excipients in oral sustained release tablets. AAPS Pharm Sci Tech 2009;10(2): p.566-73.
23.Tabasi SH, Moolchandani V, Fahmy R, Hoag SW. Sustained release dosage forms dissolution behavior prediction: A study of matrix tablets using NIR spectroscopy. Int J Pharm 2009;382: p.1-6.
24.Madgulkar AR, Bhalekar MR, Kolhe VJ, Kenjale YD. Formulation and optimization of sustained release tablets of venlafaxine resinates using response surface methodology. Ind J Pharm Sci 2009;71: p.387-94.
25.Hawaldar VD, Kulkarni AS, Dias RJ, Aloorkar NH, Mali KK. Foating matrix tablets of atenolol. Formulation and invitro evaluation. Asian J pharm. 2009;3(4): p.286-91.
.png)
